Actively Recruiting
Phase 1 Study of Valemetostat with Atezolizumab as Maintenance Treatment for Extensive-Stage Small Cell Lung Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-11
24
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and appropriate dosing of valemetostat combined with atezolizumab in people with extensive-stage small cell lung cancer SCLC. This phase 1 study aims to find the highest dose of valemetostat that causes only mild or manageable side effects. After determining this dose, the treatment will be tested in a new group to better understand its safety and potential effectiveness for this type of lung cancer. Participants will begin treatment with valemetostat taken orally once daily, starting at 150 mg, with doses possibly adjusted to 100 mg or 200 mg based on safety. Alongside this, participants will receive atezolizumab intravenously every four weeks as part of standard care. The study has two parts a dose-finding phase to establish the best valemetostat dose and an expansion phase to further assess safety and treatment effects. During the trial, participants will be monitored for side effects and treatment response over a one-year period. The main goal is to determine the recommended phase II dose of valemetostat. Researchers will also track progression-free survival for up to one year. Regular assessments including blood tests and medical evaluations will be conducted to ensure participant safety and collect important study data throughout the treatment period.
CONDITIONS
Brief Title
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Research Team
J
Jessica Ross, MD
M
Mark Awad, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
